Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunomodulatory Role and Clinical Impact of Erythromycin in Critically Septic Patients: a Randomized Clinical Trial

NCT04665089 is registered in ClinicalTrials.gov with Tunis University as lead sponsor.

NCT NCT04665089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunomodulatory Role and Clinical Impact of Erythromycin in Critically Septic Patients: a Randomized Clinical Trial
Lead sponsor
Tunis University
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2022
Completion date
April 30, 2023
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunoinflammatory response, sepsis, septic shock